Idiopathic CD4 lymphocytopenia

Joel P. Brooks, Gisoo Ghaffari

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Idiopathic CD4 lymphocytopenia (ICL) is a rare disorder of unknown etiology. Diagnostic criteria include a persistent CD4 T-cell lymphopenia with no underlying primary or secondary immune deficiencies and a CD4 T-cell count of <300 cells/mL or <20% total lymphocyte on multiple occasions. Objective: To increase awareness of ICL and to provide a review of the clinical characteristics, diagnosis, and management of this disease process. Presently, many of these patients receive prophylactic treatment similar to other T-cell deficient conditions, most notably patients with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome; however, the same indications may not necessarily apply to this patient population because the T cells are not affected by a virus as in HIV. Methods: A literature search of salient articles that describe case reports and case series of ICL and their management were analyzed. Results: A case of ICL with a literature review is presented with emphasis on clinical pearls and pitfalls. The patients with ICL are usually identified with a CD4 count of <200 cells/mL when complications develop. Opportunistic infections are the most common initial manifestations. Current therapies used to increase CD4 levels include interleukin 2, interferon gamma, interleukin 7, and allogeneic hematopoietic stem cell transplantation, with variable results. Conclusion: ICL is a diagnosis of exclusion when there is no identifiable underlying cause for a low CD4 count. Although the nature of the T-cell problem is not the same in ICL and HIV, in the absence of specific guidelines, patients receive the same prophylactic treatment as patients with HIV.

Original languageEnglish (US)
Pages (from-to)501-504
Number of pages4
JournalAllergy and Asthma Proceedings
Volume37
Issue number6
DOIs
StatePublished - Nov 1 2016

Fingerprint

Lymphopenia
T-Lymphocytes
CD4 Lymphocyte Count
HIV
Interleukin-7
Hematopoietic Stem Cell Transplantation
Opportunistic Infections
Disease Management
Interferon-gamma
Interleukin-2
Acquired Immunodeficiency Syndrome
Therapeutics
Guidelines
Lymphocytes
Viruses

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Brooks, Joel P. ; Ghaffari, Gisoo. / Idiopathic CD4 lymphocytopenia. In: Allergy and Asthma Proceedings. 2016 ; Vol. 37, No. 6. pp. 501-504.
@article{49e4362943c94fd79ce48729381b0a2e,
title = "Idiopathic CD4 lymphocytopenia",
abstract = "Background: Idiopathic CD4 lymphocytopenia (ICL) is a rare disorder of unknown etiology. Diagnostic criteria include a persistent CD4 T-cell lymphopenia with no underlying primary or secondary immune deficiencies and a CD4 T-cell count of <300 cells/mL or <20{\%} total lymphocyte on multiple occasions. Objective: To increase awareness of ICL and to provide a review of the clinical characteristics, diagnosis, and management of this disease process. Presently, many of these patients receive prophylactic treatment similar to other T-cell deficient conditions, most notably patients with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome; however, the same indications may not necessarily apply to this patient population because the T cells are not affected by a virus as in HIV. Methods: A literature search of salient articles that describe case reports and case series of ICL and their management were analyzed. Results: A case of ICL with a literature review is presented with emphasis on clinical pearls and pitfalls. The patients with ICL are usually identified with a CD4 count of <200 cells/mL when complications develop. Opportunistic infections are the most common initial manifestations. Current therapies used to increase CD4 levels include interleukin 2, interferon gamma, interleukin 7, and allogeneic hematopoietic stem cell transplantation, with variable results. Conclusion: ICL is a diagnosis of exclusion when there is no identifiable underlying cause for a low CD4 count. Although the nature of the T-cell problem is not the same in ICL and HIV, in the absence of specific guidelines, patients receive the same prophylactic treatment as patients with HIV.",
author = "Brooks, {Joel P.} and Gisoo Ghaffari",
year = "2016",
month = "11",
day = "1",
doi = "10.2500/aap.2016.37.3992",
language = "English (US)",
volume = "37",
pages = "501--504",
journal = "Allergy and Asthma Proceedings",
issn = "1088-5412",
publisher = "OceanSide Publications Inc.",
number = "6",

}

Idiopathic CD4 lymphocytopenia. / Brooks, Joel P.; Ghaffari, Gisoo.

In: Allergy and Asthma Proceedings, Vol. 37, No. 6, 01.11.2016, p. 501-504.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Idiopathic CD4 lymphocytopenia

AU - Brooks, Joel P.

AU - Ghaffari, Gisoo

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background: Idiopathic CD4 lymphocytopenia (ICL) is a rare disorder of unknown etiology. Diagnostic criteria include a persistent CD4 T-cell lymphopenia with no underlying primary or secondary immune deficiencies and a CD4 T-cell count of <300 cells/mL or <20% total lymphocyte on multiple occasions. Objective: To increase awareness of ICL and to provide a review of the clinical characteristics, diagnosis, and management of this disease process. Presently, many of these patients receive prophylactic treatment similar to other T-cell deficient conditions, most notably patients with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome; however, the same indications may not necessarily apply to this patient population because the T cells are not affected by a virus as in HIV. Methods: A literature search of salient articles that describe case reports and case series of ICL and their management were analyzed. Results: A case of ICL with a literature review is presented with emphasis on clinical pearls and pitfalls. The patients with ICL are usually identified with a CD4 count of <200 cells/mL when complications develop. Opportunistic infections are the most common initial manifestations. Current therapies used to increase CD4 levels include interleukin 2, interferon gamma, interleukin 7, and allogeneic hematopoietic stem cell transplantation, with variable results. Conclusion: ICL is a diagnosis of exclusion when there is no identifiable underlying cause for a low CD4 count. Although the nature of the T-cell problem is not the same in ICL and HIV, in the absence of specific guidelines, patients receive the same prophylactic treatment as patients with HIV.

AB - Background: Idiopathic CD4 lymphocytopenia (ICL) is a rare disorder of unknown etiology. Diagnostic criteria include a persistent CD4 T-cell lymphopenia with no underlying primary or secondary immune deficiencies and a CD4 T-cell count of <300 cells/mL or <20% total lymphocyte on multiple occasions. Objective: To increase awareness of ICL and to provide a review of the clinical characteristics, diagnosis, and management of this disease process. Presently, many of these patients receive prophylactic treatment similar to other T-cell deficient conditions, most notably patients with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome; however, the same indications may not necessarily apply to this patient population because the T cells are not affected by a virus as in HIV. Methods: A literature search of salient articles that describe case reports and case series of ICL and their management were analyzed. Results: A case of ICL with a literature review is presented with emphasis on clinical pearls and pitfalls. The patients with ICL are usually identified with a CD4 count of <200 cells/mL when complications develop. Opportunistic infections are the most common initial manifestations. Current therapies used to increase CD4 levels include interleukin 2, interferon gamma, interleukin 7, and allogeneic hematopoietic stem cell transplantation, with variable results. Conclusion: ICL is a diagnosis of exclusion when there is no identifiable underlying cause for a low CD4 count. Although the nature of the T-cell problem is not the same in ICL and HIV, in the absence of specific guidelines, patients receive the same prophylactic treatment as patients with HIV.

UR - http://www.scopus.com/inward/record.url?scp=84995572381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995572381&partnerID=8YFLogxK

U2 - 10.2500/aap.2016.37.3992

DO - 10.2500/aap.2016.37.3992

M3 - Article

C2 - 27931306

AN - SCOPUS:84995572381

VL - 37

SP - 501

EP - 504

JO - Allergy and Asthma Proceedings

JF - Allergy and Asthma Proceedings

SN - 1088-5412

IS - 6

ER -